A detailed history of Schroder Investment Management Group transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 85,999 shares of NTLA stock, worth $945,129. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,999
Previous 86,484 0.56%
Holding current value
$945,129
Previous $1.94 Million 8.68%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$19.72 - $27.36 $9,564 - $13,269
-485 Reduced 0.56%
85,999 $1.77 Million
Q2 2024

Aug 12, 2024

SELL
$20.02 - $27.22 $8,828 - $12,004
-441 Reduced 0.51%
86,484 $1.94 Million
Q1 2024

May 14, 2024

SELL
$23.82 - $32.8 $37,564 - $51,725
-1,577 Reduced 1.78%
86,925 $2.39 Million
Q4 2023

Feb 13, 2024

SELL
$23.16 - $32.34 $954,122 - $1.33 Million
-41,197 Reduced 31.76%
88,502 $2.7 Million
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $394,396 - $571,013
-12,473 Reduced 8.77%
129,699 $4.1 Million
Q2 2023

Aug 11, 2023

SELL
$34.58 - $46.03 $765,289 - $1.02 Million
-22,131 Reduced 13.47%
142,172 $5.8 Million
Q1 2023

May 11, 2023

BUY
$33.3 - $44.82 $1.89 Million - $2.54 Million
56,689 Added 52.68%
164,303 $6.12 Million
Q4 2022

Feb 10, 2023

BUY
$33.21 - $62.69 $788,870 - $1.49 Million
23,754 Added 28.33%
107,614 $3.75 Million
Q3 2022

Nov 10, 2022

SELL
$53.92 - $71.7 $411,463 - $547,142
-7,631 Reduced 8.34%
83,860 $4.69 Million
Q2 2022

Aug 11, 2022

BUY
$38.49 - $76.21 $67,126 - $132,910
1,744 Added 1.94%
91,491 $4.8 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $5.23 Million - $10.7 Million
89,747 New
89,747 $6.48 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $835M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.